← Back to headlines
Spyre Therapeutics Stock Falls on Mixed Phase 2 Trial Results
Spyre Therapeutics' stock dropped significantly after the company reported disappointing and mixed Phase 2 trial data for its rheumatoid arthritis asset, SPY072. The results have led to investor concerns regarding the drug's efficacy.
25 Aug, 20:06 — 25 Aug, 21:01
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (27/100)2 sources— more sources would strengthen this score15/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left
Center1
Center (1)
investing-com
Right1
Right (1)
seeking-alpha
Far R
Geographic diversity— 1 region4/34
US2
ℹAll sources from US region
ℹOnly 2 sources cover this story
Sources
Showing 2 of 2 sources
Coverage Timeline
First report: investing-com · 25 Aug, 20:06|Full coverage: 2 · 55m|Window: 55m
Left-leaningCenterRight-leaning
